$1.93
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Country

DE

CEO

Mr. Guido Baechler

IPO date

2021

Employees

10

ISIN

NL0015000LC2

Key stats

Open

$1.95

Volume

1.91M

Market cap

$48.27M

Prev. close

$1.94

Impl / hst vl

-

Open interest

$0.00

$1.92

Day’s Range

$1.97

$0.30

52W Range

$4.93

Valuation

22
Valuation score
Overvalued
P/E
-
P/S
-
P/B
-
Current ratio
0.50
Debt / Equity
2.62
ROE
-1,024.71%
Gross margin
79.96%
Income growth
-5.72%
FCF growth
-27.32

Analysts estimates

Consensus rating
Hold

The average rating from top 3 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy

Earnings

Q4 ‘25 revenue
$250.40K
Q4 ‘25 net income
-$7.87M
Revenue
Net income
Previous EPS
-
Estimate EPS
$0.00
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply